Kyntra Bio, Inc.
KYNB
$6.82
-$0.19-2.71%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -78.26% | 117.53% | 200.41% | -80.57% | -36.71% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -78.26% | 117.53% | 200.41% | -80.57% | -36.71% |
| Cost of Revenue | -81.81% | -75.95% | -72.17% | -69.47% | -55.15% |
| Gross Profit | 82.84% | 85.41% | 76.56% | 67.79% | 58.62% |
| SG&A Expenses | -43.83% | -20.95% | -37.56% | -40.92% | -42.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -71.50% | -65.78% | -65.13% | -63.74% | -52.38% |
| Operating Income | 70.18% | 75.80% | 68.85% | 61.77% | 54.58% |
| Income Before Tax | 61.99% | 78.17% | 65.70% | 59.04% | 52.55% |
| Income Tax Expenses | 66.54% | 80.27% | 76.71% | 14.11% | -6.75% |
| Earnings from Continuing Operations | 61.98% | 78.17% | 65.69% | 59.09% | 52.60% |
| Earnings from Discontinued Operations | 129.02% | 239.68% | 79.04% | 587.71% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 485.57% | 277.07% | 98.77% | 95.84% | 83.26% |
| EBIT | 70.18% | 75.80% | 68.85% | 61.77% | 54.58% |
| EBITDA | 70.15% | 75.83% | 68.78% | 61.52% | 54.02% |
| EPS Basic | 478.03% | 273.95% | 98.77% | 95.86% | 83.58% |
| Normalized Basic EPS | 67.38% | 73.95% | 67.56% | 61.04% | 54.96% |
| EPS Diluted | 478.03% | 273.95% | 98.77% | 95.86% | 83.58% |
| Normalized Diluted EPS | 67.38% | 73.95% | 67.56% | 61.04% | 54.96% |
| Average Basic Shares Outstanding | 1.02% | 1.84% | 2.28% | 2.52% | 3.14% |
| Average Diluted Shares Outstanding | 1.02% | 1.84% | 2.28% | 2.52% | 3.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |